Literature DB >> 23173567

The burden of influenza complications in different high-risk groups: a targeted literature review.

Josephine Mauskopf1, Mario Klesse, Seina Lee, Guillermo Herrera-Taracena.   

Abstract

OBJECTIVES: The objective was to review the published literature on seasonal influenza to assess the differences between complications and mortality rates for those adults at high risk of influenza complications, including the resource use of those hospitalized with influenza complications.
METHODS: A targeted literature review was performed using electronic database keyword searches, specific inclusion criteria, quality rating of the reviewed full-text articles and abstraction of data to present published evidence on the incidence, complication rates and health service use associated with clinical influenza in different adult high-risk groups including those who are aged 65 years and older or those with different chronic underlying medical conditions.
RESULTS: Key findings for incidence rates of clinical influenza were that incidence rates are similar among people with chronic cardiovascular or respiratory comorbidity, and may be higher in those with allogeneic stem cell transplants compared to those with autologous transplants. Rates of hospitalization and/or pneumonia or lower respiratory tract infection for those with chronic conditions or those who are immunocompromised are substantially higher than those in people over age 65 but without additional high-risk factors. A person who is hospitalized and has a laboratory-confirmed influenza diagnosis has a probability of intensive care unit admission of between 11.8-28.6% and of death of between 2.9-14.3%.
CONCLUSIONS: These findings indicate that although the burden of influenza varied across high-risk groups, it also varied widely across studies within a single high-risk group. A key finding was that those over 65 years of age but without additional high-risk factors had a low risk of influenza complications. A limitation of the review is that most of the studies of hospitalized patients did not present outcomes data separately by high-risk group and only limited data were identified on rates of hospitalization or lower respiratory tract infection for most high-risk groups. Information about influenza complication rates and resource use, including influenza vaccines, chemoprophylaxis and/or treatment strategies for different high-risk groups, is needed to evaluate new interventions.

Entities:  

Mesh:

Year:  2012        PMID: 23173567     DOI: 10.3111/13696998.2012.752376

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  37 in total

1.  Determinants of influenza vaccination among solid organ transplant recipients attending Sicilian reference center.

Authors:  Vincenzo Restivo; Giovanni Vizzini; Alessandra Mularoni; Cinzia Di Benedetto; Santi Mauro Gioè; Francesco Vitale
Journal:  Hum Vaccin Immunother       Date:  2017-02       Impact factor: 3.452

2.  Serum antioxidant status and mortality from influenza and pneumonia in US adults.

Authors:  Habyeong Kang; Howard Hu; Sung Kyun Park
Journal:  Public Health Nutr       Date:  2022-01-10       Impact factor: 4.539

3.  Flu and pulmonary fibrosis.

Authors:  Bharat Bhushan Sharma; Virendra Singh
Journal:  Lung India       Date:  2013-04

4.  Assessing optimal target populations for influenza vaccination programmes: an evidence synthesis and modelling study.

Authors:  Marc Baguelin; Stefan Flasche; Anton Camacho; Nikolaos Demiris; Elizabeth Miller; W John Edmunds
Journal:  PLoS Med       Date:  2013-10-08       Impact factor: 11.069

5.  Cost for physician-diagnosed influenza and influenza-like illnesses on primary care level in Germany--results of a database analysis from May 2010 to April 2012.

Authors:  Birgit Ehlken; Anastassia Anastassopoulou; Johannes Hain; Claudia Schröder; Klaus Wahle
Journal:  BMC Public Health       Date:  2015-06-21       Impact factor: 3.295

6.  Pneumonia and influenza, and respiratory and circulatory hospital admissions in Belgium: a retrospective database study.

Authors:  Ralph Crott; Isabelle Pouplier; Isabelle Roch; Yi-Chen Chen; Marie-Christine Closon
Journal:  Arch Public Health       Date:  2014-09-14

7.  Late regulation of immune genes and microRNAs in circulating leukocytes in a pig model of influenza A (H1N2) infection.

Authors:  Louise Brogaard; Peter M H Heegaard; Lars E Larsen; Shila Mortensen; Michael Schlegel; Ralf Dürrwald; Kerstin Skovgaard
Journal:  Sci Rep       Date:  2016-02-19       Impact factor: 4.379

8.  Molecular point-of-care testing for respiratory viruses versus routine clinical care in adults with acute respiratory illness presenting to secondary care: a pragmatic randomised controlled trial protocol (ResPOC).

Authors:  Nathan J Brendish; Ahalya K Malachira; Tristan W Clark
Journal:  BMC Infect Dis       Date:  2017-02-06       Impact factor: 3.090

9.  Immunocompromised Travelers: Demographic Characteristics, Travel Destinations, and Pretravel Health Care from the U.S. Global TravEpiNet Consortium.

Authors:  Brian S Schwartz; Jessica Rosen; Pauline V Han; Noreen A Hynes; Stefan H Hagmann; Sowmya R Rao; Emily S Jentes; Edward T Ryan; Regina C LaRocque
Journal:  Am J Trop Med Hyg       Date:  2015-08-24       Impact factor: 2.345

10.  A population-based estimate of the economic burden of influenza in Peru, 2009-2010.

Authors:  Yeny O Tinoco; Eduardo Azziz-Baumgartner; Hugo Rázuri; Matthew R Kasper; Candice Romero; Ernesto Ortiz; Jorge Gomez; Marc-Alain Widdowson; Timothy M Uyeki; Robert H Gilman; Daniel G Bausch; Joel M Montgomery
Journal:  Influenza Other Respir Viruses       Date:  2016-01-29       Impact factor: 4.380

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.